WHO. World Health Organization (WHO) Influenza (Seasonal) 2018 Available from: who.int/en/news-room/fact-sheets/detail/influenza-(seasonal).
Google Scholar
Iuliano AD, Roguski KM, Chang HH, Muscatello DJ, Palekar R, Tempia S, et al. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. Lancet. 2018;391(10127):1285–300.
PubMed
Google Scholar
Palese P. Influenza: old and new threats. Nat Med. 2004;10:S82.
CAS
PubMed
Google Scholar
WT RPA, Harmon MW, Rota JS, Kendal AP, Nerome K. Cocirculation of two distinct evolutionary lineages of influenza type B virus since 1983. Virology. 1990;175(1):59–68.
Google Scholar
Hause BM, Collin EA, Liu R, Huang B, Sheng Z, Lu W, et al. Characterization of a novel influenza virus in cattle and swine: proposal for a new genus in the Orthomyxoviridae family. MBio. 2014;5(2):e00031–14.
PubMed
PubMed Central
Google Scholar
Parvin JD, Moscona A, Pan WT, Leider JM, Palese P. Measurement of the mutation rates of animal viruses: influenza a virus and poliovirus type 1. J Virol. 1986;59(2):377–83.
CAS
PubMed
PubMed Central
Google Scholar
Webster RGLW, Air GM, Schild GC. Molecular mechanisms of variation in influenza viruses. Nature. 1982;296(5853):115–21.
CAS
PubMed
Google Scholar
Chambers BS, Parkhouse K, Ross TM, Alby K, Hensley SE. Identification of Hemagglutinin residues responsible for H3N2 antigenic drift during the 2014-2015 influenza season. Cell Rep. 2015;12(1):1–6.
CAS
PubMed
PubMed Central
Google Scholar
Garten RJ, Davis CT, Russell CA, Shu B, Lindstrom S, Balish A, et al. Antigenic and genetic characteristics of swine-origin 2009 a(H1N1) influenza viruses circulating in humans. Science. 2009;325(5937):197–201.
CAS
PubMed
PubMed Central
Google Scholar
Ferguson NM, Galvani AP, Bush RM. Ecological and immunological determinants of influenza evolution. Nature. 2003;422:428.
CAS
PubMed
Google Scholar
Bush RM, Bender CA, Subbarao K, Cox NJ, Fitch WM. Predicting the evolution of human influenza a. Science. 1999;286(5446):1921.
CAS
PubMed
Google Scholar
WHO. Global Influenza Surveillance and Response System (GISRS) Available from: https://www.who.int/influenza/gisrs_laboratory/en/.
Davenport FM. Control of influenza. Med J Aust. 1973;1:33–8.
CAS
PubMed
Google Scholar
CDC. Key Facts About Influenza (Flu) 2019 Available from: https://www.cdc.gov/flu/about/keyfacts.htm.
Google Scholar
Goodwin K, Viboud C, Simonsen L. Antibody response to influenza vaccination in the elderly: a quantitative review. Vaccine. 2006;24(8):1159–69.
CAS
PubMed
Google Scholar
Grohskopf LA, Sokolow LZ, Broder KR, Walter EB, Fry AM, Jernigan DB. Prevention and control of seasonal influenza with vaccines: recommendations of the advisory committee on immunization practices-United States, 2018-19 influenza season. MMWR Recomm Rep. 2018;67(3):1–20.
PubMed
PubMed Central
Google Scholar
Ohmit SE, Victor JC, Rotthoff JR, Teich ER, Truscon RK, Baum LL, et al. Prevention of antigenically drifted influenza by inactivated and live attenuated vaccines. N Engl J Med. 2006;355(24):2513–22.
CAS
PubMed
PubMed Central
Google Scholar
Tisa V, Barberis I, Faccio V, Paganino C, Trucchi C, Martini M, et al. Quadrivalent influenza vaccine: a new opportunity to reduce the influenza burden. J Preventive Med hygiene. 2016;57(1):E28–33.
CAS
Google Scholar
Pandey S, Manjrekar S, Sumant O. Influenza Vaccine Market by Vaccine Type (Quadrivalent and Trivalent), Type (Seasonal and Pandemic), Technology (Egg-based and Cell-based), Age Group (Pediatric and Adult), and Route of Administration (Injection and Nasal Spray): Global Opportunity Analysis and Industry Forecast, 2019–2026. Portland: Allied Market Research; 2019. Available from: https://www.alliedmarketresearch.com/influenza-vaccines-market.
McLean KA, Goldin S, Nannei C, Sparrow E, Torelli G. The 2015 global production capacity of seasonal and pandemic influenza vaccine. Vaccine. 2016;34(45):5410–3.
PubMed
PubMed Central
Google Scholar
WHO. Addendum to the recommended composition of influenza virus vaccines for use in the 2019–2020 northern hemisphere influenza season 2019. Available from: https://www.who.int/influenza/vaccines/virus/recommendations/201902_recommendation_addendum.pdf?ua=1. [cited 2019 11/14].
Abelin A, Colegate T, Gardner S, Hehme N, Palache A. Lessons from pandemic influenza a(H1N1): the research-based vaccine industry's perspective. Vaccine. 2011;29(6):1135–8.
PubMed
Google Scholar
Skowronski DM, Janjua NZ, De Serres G, Sabaiduc S, Eshaghi A, Dickinson JA, et al. Low 2012–13 influenza vaccine effectiveness associated with mutation in the egg-adapted H3N2 vaccine strain not antigenic drift in circulating viruses. PLoS One. 2014;9(3):e92153.
PubMed
PubMed Central
Google Scholar
Zost SJ, Parkhouse K, Gumina ME, Kim K, Diaz Perez S, Wilson PC, et al. Contemporary H3N2 influenza viruses have a glycosylation site that alters binding of antibodies elicited by egg-adapted vaccine strains. Proc Natl Acad Sci. 2017;114(47):12578.
CAS
PubMed
PubMed Central
Google Scholar
Widjaja L, Ilyushina N, Webster RG, Webby RJ. Molecular changes associated with adaptation of human influenza a virus in embryonated chicken eggs. Virol. 2006;350(1):137–45.
CAS
Google Scholar
Nicholls JM, Chan RWY, Russell RJ, Air GM, Peiris JSM. Evolving complexities of influenza virus and its receptors. Trends Microbiol. 2008;16(4):149–57.
CAS
PubMed
Google Scholar
Imai M, Kawaoka Y. The role of receptor binding specificity in interspecies transmission of influenza viruses. Curr Opinion Virol. 2012;2(2):160–7.
CAS
Google Scholar
Ito T, Suzuki Y, Takada A, Kawamoto A, Otsuki K, Masuda H, et al. Differences in sialic acid-galactose linkages in the chicken egg amnion and allantois influence human influenza virus receptor specificity and variant selection. J Virol. 1997;71(4):3357–62.
CAS
PubMed
PubMed Central
Google Scholar
Hoft DF, Babusis E, Worku S, Spencer CT, Lottenbach K, Truscott SM, et al. Live and inactivated influenza vaccines induce similar humoral responses, but only live vaccines induce diverse T-cell responses in young children. J Infect Dis. 2011;204(6):845–53.
CAS
PubMed
PubMed Central
Google Scholar
Mohn KG-I, Brokstad KA, Pathirana RD, Bredholt G, Jul-Larsen Å, Trieu MC, et al. Live attenuated influenza vaccine in children induces B-cell responses in tonsils. J Infect Dis. 2016;214(5):722–31.
CAS
PubMed
PubMed Central
Google Scholar
Gaglani M, Pruszynski J, Murthy K, Clipper L, Robertson A, Reis M, et al. Influenza vaccine effectiveness against 2009 pandemic influenza a(H1N1) virus differed by vaccine type during 2013-2014 in the United States. J Infect Dis. 2016;213(10):1546–56.
PubMed
PubMed Central
Google Scholar
Tam TWS. Intranasal influenza vaccine: why does Canada have different recommendations from the USA on its use? Paediatr Child Health. 2018;23(1):31–4.
PubMed
PubMed Central
Google Scholar
Singanayagam A, Zambon M, Lalvani A, Barclay W. Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infect Dis. 2018;18(1):e25–32.
PubMed
Google Scholar
Grohskopf LA, Sokolow LZ, Fry AM, Walter EB, Jernigan DB. Update: ACIP recommendations for the use of quadrivalent live attenuated influenza vaccine (LAIV4)—United States, 2018–19 influenza season. Morb Mortal Wkly Rep. 2018;67(22):643.
Google Scholar
Immunization NACo. An Advisory Committee Statement (ACS): Canadian Immunization Guide Chapter on Influenza and Statement on Seasonal Influenza Vaccine for 2019-2020. Ottawa: Public Health Agency Of Canada; 2018.
Google Scholar
CDC. Flublok Seasonal Influenza (Flu) Vaccine [Available from: https://www.cdc.gov/flu/protect/vaccine/qa_flublok-vaccine.htm.
Cox MMJ, Izikson R, Post P, Dunkle L. Safety, efficacy, and immunogenicity of Flublok in the prevention of seasonal influenza in adults. Therapeutic Advances Vaccin. 2015;3(4):97–108.
CAS
Google Scholar
Izurieta HS, Chillarige Y, Kelman J, Wei Y, Lu Y, Xu W, et al. Relative effectiveness of cell-cultured and egg-based influenza vaccines among elderly persons in the United States, 2017-2018. J Infect Dis. 2019;220(8):1255–64.
CAS
PubMed
Google Scholar
Cox MMJ, Hashimoto Y. A fast track influenza virus vaccine produced in insect cells. J Invertebr Pathol. 2011;107:S31–41.
CAS
PubMed
Google Scholar
Dunkle LM, Izikson R, Patriarca P, Goldenthal KL, Muse D, Callahan J, et al. Efficacy of recombinant influenza vaccine in adults 50 years of age or older. N Engl J Med. 2017;376(25):2427–36.
CAS
PubMed
Google Scholar
CDC. Archived CDC Vaccine Price List as of 1 September 2019. Available from: https://www.cdc.gov/vaccines/programs/vfc/awardees/vaccine-management/price-list/index.html.
The White House, Office of the Press Secretary. Statement from the Press Secretary on the Executive Order Modernizing Influenza Vaccines in the U.S. to Promote National Security and Public Health [press release] (2019 Sep 19). Available from: https://www.whitehouse.gov/briefings-statements/statement-press-secretary-executive-order-modernizing-influenza-vaccines-u-s-promote-national-security-public-health/. Cited 2020 Feb 3.
Paules CI, Marston HD, Eisinger RW, Baltimore D, Fauci AS. The pathway to a universal influenza vaccine. Immunity. 2017;47(4):599–603.
CAS
PubMed
Google Scholar
Sah P, Alfaro-Murillo JA, Fitzpatrick MC, Neuzil KM, Meyers LA, Singer BH, et al. Future epidemiological and economic impacts of universal influenza vaccines. Proc Natl Acad Sci. 2019;116(41):20786–92.
CAS
PubMed
PubMed Central
Google Scholar
Smith G, Liu Y, Flyer D, Massare MJ, Zhou B, Patel N, et al. Novel hemagglutinin nanoparticle influenza vaccine with matrix-M adjuvant induces hemagglutination inhibition, neutralizing, and protective responses in ferrets against homologous and drifted a(H3N2) subtypes. Vaccine. 2017;35(40):5366–72.
CAS
PubMed
Google Scholar
Shinde V, Fries L, Wu Y, Agrawal S, Cho I, Thomas DN, et al. Improved titers against influenza drift variants with a nanoparticle vaccine. N Engl J Med. 2018;378(24):2346–8.
PubMed
Google Scholar
Lovgren Bengtsson K, Morein B, Osterhaus AD. ISCOM technology-based matrix M adjuvant: success in future vaccines relies on formulation. Expert Rev Vaccines. 2011;10(4):401–3.
PubMed
Google Scholar
Krammer F, Pica N, Hai R, Margine I, Palese P. Chimeric hemagglutinin influenza virus vaccine constructs elicit broadly protective stalk-specific antibodies. J Virol. 2013;87(12):6542–50.
CAS
PubMed
PubMed Central
Google Scholar
Nachbagauer R, Liu WC, Choi A, Wohlbold TJ, Atlas T, Rajendran M, et al. A universal influenza virus vaccine candidate confers protection against pandemic H1N1 infection in preclinical ferret studies. NPJ Vaccines. 2017;2:26.
PubMed
PubMed Central
Google Scholar
Krammer F, Margine I, Hai R, Flood A, Hirsh A, Tsvetnitsky V, et al. H3 stalk-based chimeric hemagglutinin influenza virus constructs protect mice from H7N9 challenge. J Virol. 2014;88(4):2340–3.
PubMed
PubMed Central
Google Scholar
Krammer F, Palese P, Steel J. Advances in universal influenza virus vaccine design and antibody mediated therapies based on conserved regions of the hemagglutinin. Curr Top Microbiol Immunol. 2015;386:301–21.
CAS
PubMed
Google Scholar
Wang CC, Chen JR, Tseng YC, Hsu CH, Hung YF, Chen SW, et al. Glycans on influenza hemagglutinin affect receptor binding and immune response. Proc Natl Acad Sci U S A. 2009;106(43):18137–42.
CAS
PubMed
PubMed Central
Google Scholar
Chen JR, Yu YH, Tseng YC, Chiang WL, Chiang MF, Ko YA, et al. Vaccination of monoglycosylated hemagglutinin induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci U S A. 2014;111(7):2476–81.
CAS
PubMed
PubMed Central
Google Scholar
Tseng YC, Wu CY, Liu ML, Chen TH, Chiang WL, Yu YH, et al. Egg-based influenza split virus vaccine with monoglycosylation induces cross-strain protection against influenza virus infections. Proc Natl Acad Sci U S A. 2019;116(10):4200–5.
CAS
PubMed
PubMed Central
Google Scholar
Atsmon J, Caraco Y, Ziv-Sefer S, Shaikevich D, Abramov E, Volokhov I, et al. Priming by a novel universal influenza vaccine (Multimeric-001)-a gateway for improving immune response in the elderly population. Vaccine. 2014;32(44):5816–23.
CAS
PubMed
Google Scholar
Gottlieb T, Ben-Yedidia T. Epitope-based approaches to a universal influenza vaccine. J Autoimmun. 2014;54:15–20.
CAS
PubMed
Google Scholar
Atsmon J, Kate-Ilovitz E, Shaikevich D, Singer Y, Volokhov I, Haim KY, et al. Safety and immunogenicity of multimeric-001--a novel universal influenza vaccine. J Clin Immunol. 2012;32(3):595–603.
CAS
PubMed
Google Scholar
van Doorn E, Liu H, Ben-Yedidia T, Hassin S, Visontai I, Norley S, et al. Evaluating the immunogenicity and safety of a BiondVax-developed universal influenza vaccine (Multimeric-001) either as a standalone vaccine or as a primer to H5N1 influenza vaccine: phase IIb study protocol. Medicine (Baltimore). 2017;96(11):e6339.
Google Scholar
Stoloff GA, Caparros-Wanderley W. Synthetic multi-epitope peptides identified in silico induce protective immunity against multiple influenza serotypes. Eur J Immunol. 2007;37(9):2441–9.
CAS
PubMed
Google Scholar
Pleguezuelos O, Robinson S, Stoloff GA, Caparros-Wanderley W. Synthetic influenza vaccine (FLU-v) stimulates cell mediated immunity in a double-blind, randomised, placebo-controlled phase I trial. Vaccine. 2012;30(31):4655–60.
CAS
PubMed
Google Scholar
van Doorn E, Pleguezuelos O, Liu H, Fernandez A, Bannister R, Stoloff G, et al. Evaluation of the immunogenicity and safety of different doses and formulations of a broad spectrum influenza vaccine (FLU-v) developed by SEEK: study protocol for a single-center, randomized, double-blind and placebo-controlled clinical phase IIb trial. BMC Infect Dis. 2017;17(1):241.
PubMed
PubMed Central
Google Scholar
Pleguezuelos O, Robinson S, Fernandez A, Stoloff GA, Mann A, Gilbert A, et al. A synthetic influenza virus vaccine induces a cellular immune response that correlates with reduction in symptomatology and virus shedding in a randomized phase Ib live-virus challenge in humans. Clin Vaccine Immunol. 2015;22(7):828–35.
CAS
PubMed
PubMed Central
Google Scholar
Mitchell CA, Ramessar K, O'Keefe BR. Antiviral lectins: selective inhibitors of viral entry. Antivir Res. 2017;142:37–54.
CAS
PubMed
Google Scholar
Mueller S, Coleman JR, Papamichail D, Ward CB, Nimnual A, Futcher B, et al. Live attenuated influenza virus vaccines by computer-aided rational design. Nat Biotechnol. 2010;28(7):723–6.
CAS
PubMed
PubMed Central
Google Scholar
Yang C, Skiena S, Futcher B, Mueller S, Wimmer E. Deliberate reduction of hemagglutinin and neuraminidase expression of influenza virus leads to an ultraprotective live vaccine in mice. Proc Natl Acad Sci U S A. 2013;110(23):9481–6.
CAS
PubMed
PubMed Central
Google Scholar
Stauft CB, Yang C, Coleman JR, Boltz D, Chin C, Kushnir A, et al. Live-attenuated H1N1 influenza vaccine candidate displays potent efficacy in mice and ferrets. PLoS One. 2019;14(10):e0223784.
CAS
PubMed
PubMed Central
Google Scholar
Sarawar S, Hatta Y, Watanabe S, Dias P, Neumann G, Kawaoka Y, et al. M2SR, a novel live single replication influenza virus vaccine, provides effective heterosubtypic protection in mice. Vaccine. 2016;34(42):5090–8.
CAS
PubMed
PubMed Central
Google Scholar
Hatta Y, Boltz D, Sarawar S, Kawaoka Y, Neumann G, Bilsel P. Novel influenza vaccine M2SR protects against drifted H1N1 and H3N2 influenza virus challenge in ferrets with pre-existing immunity. Vaccine. 2018;36(33):5097–103.
CAS
PubMed
PubMed Central
Google Scholar
Elliott STC, Keaton AA, Chu JD, Reed CC, Garman B, Patel A, et al. A synthetic micro-consensus DNA vaccine generates comprehensive influenza a H3N2 immunity and protects mice against lethal challenge by multiple H3N2 viruses. Hum Gene Ther. 2018;29(9):1044–55.
CAS
PubMed
PubMed Central
Google Scholar
Yan J, Morrow MP, Chu JS, Racine T, Reed CC, Khan AS, et al. Broad cross-protective anti-hemagglutination responses elicited by influenza microconsensus DNA vaccine. Vaccine. 2018;36(22):3079–89.
CAS
PubMed
Google Scholar
Yan J, Villarreal DO, Racine T, Chu JS, Walters JN, Morrow MP, et al. Protective immunity to H7N9 influenza viruses elicited by synthetic DNA vaccine. Vaccine. 2014;32(24):2833–42.
CAS
PubMed
PubMed Central
Google Scholar
Choo AY, Broderick KE, Kim JJ, Sardesai NY. DNA-based influenza vaccines: evaluating their potential to provide universal protection. IDrugs. 2010;13(10):707–12.
CAS
PubMed
Google Scholar
De Filette M, Martens W, Smet A, Schotsaert M, Birkett A, Londono-Arcila P, et al. Universal influenza a M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies. Vaccine. 2008;26(51):6503–7.
PubMed
Google Scholar
Deng L, Cho KJ, Fiers W, Saelens X. M2e-based universal influenza a vaccines. Vaccines (Basel). 2015;3(1):105–36.
CAS
Google Scholar
O'Donnell CD, Wright A, Vogel LN, Wei CJ, Nabel GJ, Subbarao K. Effect of priming with H1N1 influenza viruses of variable antigenic distances on challenge with 2009 pandemic H1N1 virus. J Virol. 2012;86(16):8625–33.
CAS
PubMed
PubMed Central
Google Scholar
Tate MD, Job ER, Deng YM, Gunalan V, Maurer-Stroh S, Reading PC. Playing hide and seek: how glycosylation of the influenza virus hemagglutinin can modulate the immune response to infection. Viruses. 2014;6(3):1294–316.
PubMed
PubMed Central
Google Scholar
Medina RA, Stertz S, Manicassamy B, Zimmermann P, Sun X, Albrecht RA, et al. Glycosylations in the globular head of the hemagglutinin protein modulate the virulence and antigenic properties of the H1N1 influenza viruses. Sci Transl Med. 2013;5(187):187ra70.
PubMed
PubMed Central
Google Scholar
Kobayashi Y, Suzuki Y. Evidence for N-glycan shielding of antigenic sites during evolution of human influenza a virus hemagglutinin. J Virol. 2012;86(7):3446–51.
CAS
PubMed
PubMed Central
Google Scholar
Wei CJ, Boyington JC, Dai K, Houser KV, Pearce MB, Kong WP, et al. Cross-neutralization of 1918 and 2009 influenza viruses: role of glycans in viral evolution and vaccine design. Sci Transl Med. 2010;2(24):24ra1.
Google Scholar
Abe Y, Takashita E, Sugawara K, Matsuzaki Y, Muraki Y, Hongo S. Effect of the addition of oligosaccharides on the biological activities and antigenicity of influenza a/H3N2 virus Hemagglutinin. J Virol. 2004;78(18):9605–11.
CAS
PubMed
PubMed Central
Google Scholar
Chen JR, Ma C, Wong CH. Vaccine design of hemagglutinin glycoprotein against influenza. Trends Biotechnol. 2011;29(9):426–34.
CAS
PubMed
Google Scholar
Zhou T, Doria-Rose NA, Cheng C, Stewart-Jones GBE, Chuang GY, Chambers M, et al. Quantification of the impact of the HIV-1-glycan shield on antibody elicitation. Cell Rep. 2017;19(4):719–32.
CAS
PubMed
PubMed Central
Google Scholar
Hurtley SM, Bole DG, Hoover-Litty H, Helenius A, Copeland CS. Interactions of misfolded influenza virus hemagglutinin with binding protein (BiP). J Cell Biol. 1989;108(6):2117–26.
CAS
PubMed
Google Scholar
Roberts PC, Garten W, Klenk HD. Role of conserved glycosylation sites in maturation and transport of influenza a virus hemagglutinin. J Virol. 1993;67(6):3048–60.
CAS
PubMed
PubMed Central
Google Scholar
Lowell GH, Ziv S, Bruzil S, Babecoff R, Ben-Yedidia T. Back to the future: immunization with M-001 prior to trivalent influenza vaccine in 2011/12 enhanced protective immune responses against 2014/15 epidemic strain. Vaccine. 2017;35(5):713–5.
CAS
PubMed
Google Scholar
Saelens X. The Role of Matrix Protein 2 Ectodomain in the Development of Universal Influenza Vaccines. J Infect Dis. 2019;219(Supplement 1):S68–74.
CAS
PubMed
PubMed Central
Google Scholar
Erbelding EJ, Post DJ, Stemmy EJ, Roberts PC, Augustine AD, Ferguson S, et al. A universal influenza vaccine: the strategic plan for the National Institute of Allergy and Infectious Diseases. J Infect Dis. 2018;218(3):347–54.
CAS
PubMed
PubMed Central
Google Scholar
Wijnans L, Voordouw B. A review of the changes to the licensing of influenza vaccines in Europe. Influenza Other Respir Viruses. 2016;10(1):2–8.
PubMed
Google Scholar
Weir JP, Gruber MF. An overview of the regulation of influenza vaccines in the United States. Influenza Other Respir Viruses. 2016;10(5):354–60.
PubMed
PubMed Central
Google Scholar
Schild GC, Pereira MS, Chakraverty P. Single-radial-hemolysis: a new method for the assay of antibody to influenza haemagglutinin. Applications for diagnosis and seroepidemiologic surveillance of influenza. Bull World Health Organ. 1975;52(1):43–50.
CAS
PubMed
PubMed Central
Google Scholar
Gianchecchi E, Torelli A, Montomoli E. The use of cell-mediated immunity for the evaluation of influenza vaccines: an upcoming necessity. Human Vaccin Immunotherapeutics. 2019;15(5):1021–30.
CAS
Google Scholar
Oxford JS, Oxford JR. Clinical, scientific and ethnographic studies of influenza in quarantine. Expert Rev Vaccin. 2012;11(8):929–37.
CAS
Google Scholar
Oxford JS, Gelder C, Lambkin R. Would you volunteer to be quarantined and infected with influenza virus? Expert Rev Anti-Infect Ther. 2005;3(1):1–2.
PubMed
Google Scholar
Wilkinson TM, Li CK, Chui CS, Huang AK, Perkins M, Liebner JC, et al. Preexisting influenza-specific CD4+ T cells correlate with disease protection against influenza challenge in humans. Nat Med. 2012;18(2):274–80.
CAS
PubMed
Google Scholar
Govaert TM, Thijs CT, Masurel N, Sprenger MJ, Dinant GJ, Knottnerus JA. The efficacy of influenza vaccination in elderly individuals. A randomized double-blind placebo-controlled trial. JAMA. 1994;272(21):1661–5.
CAS
PubMed
Google Scholar
Petrie JG, Ohmit SE, Truscon R, Johnson E, Braun TM, Levine MZ, et al. Modest waning of influenza vaccine efficacy and antibody titers during the 2007-2008 influenza season. J Infect Dis. 2016;214(8):1142–9.
CAS
PubMed
Google Scholar
Ferdinands JM, Fry AM, Reynolds S, Petrie JG, Flannery B, Jackson ML, et al. Intraseason waning of influenza vaccine protection: evidence from the US influenza vaccine effectiveness network, 2011–2012 through 2014–2015. Clin Infect Dis. 2017;64(5):544–50.
PubMed
Google Scholar
Organization WH. WHO preferred product characteristics for next generation influenza vaccines. 2017.
Google Scholar
Chai N, Swem LR, Reichelt M, Chen-Harris H, Luis E, Park S, et al. Two escape mechanisms of influenza a virus to a broadly neutralizing stalk-binding antibody. PLoS Pathog. 2016;12(6):e1005702.
PubMed
PubMed Central
Google Scholar
Doud MB, Lee JM, Bloom JD. How single mutations affect viral escape from broad and narrow antibodies to H1 influenza hemagglutinin. Nat Commun. 2018;9(1):1386.
PubMed
PubMed Central
Google Scholar
Marcelin G, Sandbulte MR, Webby RJ. Contribution of antibody production against neuraminidase to the protection afforded by influenza vaccines. Rev Med Virol. 2012;22(4):267–79.
CAS
PubMed
PubMed Central
Google Scholar